FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 251 filers reported holding FATE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $7,754,000 | +32.4% | 200,000 | 0.0% | 0.64% | -11.4% |
Q4 2021 | $5,856,851 | -1.3% | 200,000 | 0.0% | 0.72% | -12.1% |
Q3 2021 | $5,932,927 | -31.7% | 200,000 | 0.0% | 0.82% | -33.3% |
Q2 2021 | $8,687,679 | +5.3% | 200,000 | 0.0% | 1.24% | -4.2% |
Q1 2021 | $8,253,245 | -9.3% | 200,000 | 0.0% | 1.29% | -10.9% |
Q4 2020 | $9,102,093 | – | 200,000 | – | 1.45% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
XTX Topco Ltd | 192,920 | $408,990 | 0.07% |